R+Cu's Cancer Treatment: Balancing Hope and Hype
Written by Arushi Sharma
Researchers in India have developed a potentially groundbreaking and affordable cancer treatment that could prevent cancer recurrence.
In a potentially groundbreaking development, researchers at the Tata Institute of Mumbai have unveiled a novel and affordable cancer treatment with the potential to prevent cancer recurrence.
The innovation comes in the form of a ₹100 pro-oxidant tablet named R+Cu, comprising resveratrol and copper.
This tablet specifically targets cell fragments known as cell-free chromatin particles (cfChPs), released by dying cancer cells, which can trigger the recurrence of cancer in healthy cells.
R+Cu generates oxygen radicals in the stomach, entering the bloodstream to effectively destroy these harmful cfChPs.
Pre-clinical trials on rats have shown promising results, indicating a 50 percent reduction in chemotherapy and radiation side effects.
While early findings suggest a 30 percent effectiveness in preventing cancer recurrence, human trials for prevention are pending. If successful, the tablet aims for approval from India’s food safety agency, with human clinical trials expected to commence by June-July 2024.